Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for ...
Analysts say second fatality heightens safety concerns, raises doubts about future demand Both patients suffered from acute liver failure Sarepta suspends forecast, stops shipments of therapy to some ...
As we continue our series exploring genetic medicine, both in this story and in Destiny's Child No Longer: Rewriting Genetic Fate, gene therapy stands at a crossroads. On June 16, Sarepta Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results